4 results
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
ELOC may cause the price of our Common Stock to decline.
Item 1B. Unresolved Staff Comments.
None.
Item 1C. Cybersecurity
Risk management … ongoing research into our drug therapies]. Therefore, we do not consider that we face significant cybersecurity risk and have not adopted a formal
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
ELOC may cause the price of our Common Stock to decline.
Item 1B. Unresolved Staff Comments.
None.
Item 1C. Cybersecurity
Risk management … ongoing research into our drug therapies]. Therefore, we do not consider that we face significant cybersecurity risk and have not adopted a formal
10-K
2023 FY
EX-19.1
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
objectives, operations, business plans, or strategy, or a restructuring;
A significant cybersecurity incident, such as a data breach, or any other
10-K
2023 FY
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
may cause the price of our Common Stock to decline.
Item 1B. Unresolved Staff Comments.
None.
Item 1C. Cybersecurity
Risk management and strategy … ongoing research into our drug therapies]. Therefore, we do not consider that we face significant cybersecurity risk and have not adopted a formal
- Prev
- 1
- Next